Drug intelligence / Profile preview

PMI04

Development stage: Unknown
Lead developer: Neuraly
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PMI04 is a PET imaging biomarker developed by Neuraly, a subsidiary of D&D Pharmatech. It selectively binds to the Colony Stimulating Factor 1 Receptor (CSF-1R) expressed in activated microglia, enabling the visualization of neuroinflammatory responses. This specificity makes PMI04 a promising tool for diagnosing neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on PMI04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMI04.

Explore the full profile